|
gptkbp:instanceOf
|
gptkb:cytotoxic_compound
gptkb:antineoplastic_agent
gptkb:antibiotic
|
|
gptkbp:administeredBy
|
intravenous injection
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01DA01
|
|
gptkbp:CASNumber
|
50-76-0
|
|
gptkbp:category
|
gptkb:antineoplastic_agent
gptkb:polypeptide_antibiotic
|
|
gptkbp:chemicalFormula
|
C62H86N12O16
|
|
gptkbp:color
|
red-orange crystals
|
|
gptkbp:contraindication
|
pregnancy
liver impairment
|
|
gptkbp:discoveredBy
|
gptkb:Selman_Waksman
|
|
gptkbp:discoveredIn
|
1940
|
|
gptkbp:eliminatedIn
|
renal excretion
biliary excretion
|
|
gptkbp:firstAntibiotic
|
first antibiotic shown to have anti-cancer activity
|
|
gptkbp:halfLife
|
36 hours
|
|
gptkbp:interactsWith
|
gptkb:radiation_therapy
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits DNA-dependent RNA synthesis
intercalates into DNA
|
|
gptkbp:meltingPoint
|
250°C (decomposes)
|
|
gptkbp:metabolism
|
not significantly metabolized
|
|
gptkbp:molecularWeight
|
1255.42 g/mol
|
|
gptkbp:origin
|
gptkb:natural_product
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:producedBy
|
Streptomyces parvulus
|
|
gptkbp:PubChem_CID
|
2019
CHEMBL325
DB00970
|
|
gptkbp:riskFactor
|
vesicant (causes tissue damage if extravasated)
|
|
gptkbp:sideEffect
|
nausea
vomiting
hair loss
bone marrow suppression
|
|
gptkbp:solubility
|
slightly soluble in water
|
|
gptkbp:structure
|
contains phenoxazinone chromophore
|
|
gptkbp:synonym
|
gptkb:dactinomycin
|
|
gptkbp:toxicity
|
highly toxic
|
|
gptkbp:UNII
|
1CC1JFE158
|
|
gptkbp:usedFor
|
gptkb:Wilms_tumor
gptkb:cancer
gptkb:rhabdomyosarcoma
gestational trophoblastic neoplasia
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Cosmegen
gptkb:actinomycin
gptkb:choriocarcinoma
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
actinomycin D
|